News

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...
GlobalData on MSN1d
Roche and Genentech’s Lunsumio-Polivy shows promise in Phase III trial
Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...
Fierce Pharma1d
Roche's bispecific-ADC combo keeps cancer at bay in 2nd shot at 2nd-line large B-cell lymphoma
Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...
The Pharma Letter1d
Positive new data on Roche’s Lunsumio and Polivy combo
Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), ...
Morningstar4d
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered ...
Yahoo Finance4d
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
The National Comprehensive Cancer Network® (NCCN®) has recently added Lunsumio and Polivy to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A recommendation for ...